Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-07-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/dr/article/view/10379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850070734482702336 |
|---|---|
| author | Andrea D'Arino Maria Concetta Fargnoli Pasquale Frascione Chiara Assorgi Annunziata Dattola Viviana Lora Matteo Megna Flavia Pigliacelli Emanuele Vagnozzi Diego Orsini |
| author_facet | Andrea D'Arino Maria Concetta Fargnoli Pasquale Frascione Chiara Assorgi Annunziata Dattola Viviana Lora Matteo Megna Flavia Pigliacelli Emanuele Vagnozzi Diego Orsini |
| author_sort | Andrea D'Arino |
| collection | DOAJ |
| description |
Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several small studies and case reports that provide evidence for the potential use of biologic therapies in the treatment of erythrodermic psoriasis. This case series suggests that risankizumab may represent an effective and sustainable treatment option for patients with a history of EP.
|
| format | Article |
| id | doaj-art-0eee4fc5a02e49759fc7d4cb40e4df1f |
| institution | DOAJ |
| issn | 2036-7392 2036-7406 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj-art-0eee4fc5a02e49759fc7d4cb40e4df1f2025-08-20T02:47:28ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062025-07-0110.4081/dr.2025.10379Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case seriesAndrea D'Arino0https://orcid.org/0000-0002-0669-1442Maria Concetta Fargnoli1https://orcid.org/0000-0002-7249-2556Pasquale Frascione2https://orcid.org/0000-0002-5592-8485Chiara Assorgi3Annunziata Dattola4https://orcid.org/0000-0001-9504-5882Viviana Lora5Matteo Megna6Flavia Pigliacelli7Emanuele Vagnozzi8Diego Orsini9Oncologic and Preventive Dermatology Unit, IRCCS San Gallicano Dermatological Institute, RomeScientific Direction, IRCCS San Gallicano Dermatological Institute, RomeOncologic and Preventive Dermatology Unit, IRCCS San Gallicano Dermatological Institute, RomeDermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, RomeDermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, RomeClinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, RomeSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico IIClinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, RomeDermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, RomeClinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several small studies and case reports that provide evidence for the potential use of biologic therapies in the treatment of erythrodermic psoriasis. This case series suggests that risankizumab may represent an effective and sustainable treatment option for patients with a history of EP. https://www.pagepress.org/journals/dr/article/view/10379Psoriasisrisankizumaberythrodermic psoriasissafetyefficacy |
| spellingShingle | Andrea D'Arino Maria Concetta Fargnoli Pasquale Frascione Chiara Assorgi Annunziata Dattola Viviana Lora Matteo Megna Flavia Pigliacelli Emanuele Vagnozzi Diego Orsini Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series Dermatology Reports Psoriasis risankizumab erythrodermic psoriasis safety efficacy |
| title | Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series |
| title_full | Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series |
| title_fullStr | Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series |
| title_full_unstemmed | Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series |
| title_short | Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series |
| title_sort | efficacy and safety of risankizumab in patients with erythrodermic and sub erythrodermic psoriasis a case series |
| topic | Psoriasis risankizumab erythrodermic psoriasis safety efficacy |
| url | https://www.pagepress.org/journals/dr/article/view/10379 |
| work_keys_str_mv | AT andreadarino efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT mariaconcettafargnoli efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT pasqualefrascione efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT chiaraassorgi efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT annunziatadattola efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT vivianalora efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT matteomegna efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT flaviapigliacelli efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT emanuelevagnozzi efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries AT diegoorsini efficacyandsafetyofrisankizumabinpatientswitherythrodermicandsuberythrodermicpsoriasisacaseseries |